Drug news
IQWiG considers Jetrea offers major benefits for VMT
The German health technology appraisal institute, IQWiG, considers that Jetrea (ocriplasmin) from Thrombogenics, offers "major" and "considerable" benefits over standard of care.
IQWiG, stated that there is an "indication" that Jetrea offers "major" additional benefit compared with watchful waiting for Vitreomacular Adhesions (VMT) patients with mild visual impairment. There is also an indication of considerable added benefit for patients with moderate visual impairment.